Ubs Asset Management Americas Inc Fate Therapeutics Inc Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 142,131 shares of FATE stock, worth $315,530. This represents 0.0% of its overall portfolio holdings.

Number of Shares

142,131

Previous 188,460 24.58%

Holding current value

$315,530

Previous $618,000 19.58%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $144,546 - $258,052	-46,329 Reduced 24.58%	142,131 $497,000
Q2 2024 Aug 13, 2024	BUY	$3.26 - $7.08 $614,379 - $1.33 Million	188,460 New	188,460 $618,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $181,230 - $475,302	-42,743 Reduced 54.69%	35,408 $201,000
Q4 2022 Feb 14, 2023	SELL	$9.86 - $23.83 $3.28 Million - $7.93 Million	-332,742 Reduced 80.98%	78,151 $788,000
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $2.17 Million - $3.72 Million	-103,204 Reduced 20.07%	410,893 $9.21 Million
Q2 2022 Aug 12, 2022	BUY	$17.78 - $42.39 $1.25 Million - $2.97 Million	70,047 Added 15.77%	514,097 $12.7 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $495,696 - $1.01 Million	16,707 Added 3.91%	444,050 $17.2 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $3.25 Million - $4.37 Million	67,934 Added 18.9%	427,343 $25 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $938,955 - $1.52 Million	15,842 Added 4.61%	359,409 $21.3 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $2.96 Million - $4.07 Million	43,974 Added 14.68%	343,567 $29.8 Million
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $8 Million - $13 Million	-110,832 Reduced 27.0%	299,593 $24.7 Million
Q4 2020 Mar 01, 2021	SELL	$38.09 - $100.95 $5.98 Million - $15.9 Million	-157,111 Reduced 27.68%	410,425 $37.3 Million
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $318,149 - $423,711	10,462 Added 1.88%	567,536 $22.7 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $3.85 Million - $6.71 Million	190,517 Added 51.97%	557,074 $19.1 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $3.2 Million - $5.9 Million	-184,939 Reduced 33.53%	366,557 $8.14 Million
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $2,945 - $4,560	220 Added 0.04%	551,496 $10.8 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $190,977 - $277,762	12,345 Added 2.29%	551,276 $8.56 Million
Q2 2019 Aug 15, 2019	BUY	$15.61 - $20.44 $112,860 - $147,781	7,230 Added 1.36%	538,931 $0
Q1 2019 May 14, 2019	BUY	$13.15 - $18.71 $239,290 - $340,465	18,197 Added 3.54%	531,701 $0
Q4 2018 Feb 13, 2019	BUY	$11.48 - $16.98 $5.14 Million - $7.6 Million	447,726 Added 680.66%	513,504 $6.59 Million
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $575,557 - $1.07 Million	65,778 New	65,778 $0

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Fate Therapeutics Inc Transaction History